059210 — Metabiomed Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapContrarian

Annual income statement for Metabiomed Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	58,780	68,942	83,101	94,036	102,951
Cost of Revenue
Gross Profit	25,003	29,196	37,990	47,361	53,593
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	54,380	64,064	73,368	76,814	81,590
Operating Profit	4,401	4,878	9,733	17,222	21,361
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	7,584	2,910	7,800	23,297	12,593
Provision for Income Taxes
Net Income After Taxes	9,521	2,846	10,023	22,150	10,772
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	9,522	2,628	10,076	22,402	10,988
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	9,522	2,628	10,076	22,402	10,988
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	402	101	478	820	389
Dividends per Share